Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of EDP1815 in atopic dermatitis
2022-000284-48Phase 2Terminated
- Sponsor
- Evelo Biosciences
- Start
- May 2022
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of EDP1815 in atopic dermatitis (AD), sponsored by Evelo Biosciences. Primary endpoint: Treatment-emergent adverse events. Started May 2022; status: terminated.
02
Drugs
EDP1815
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2022-000284-48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000284-48.